Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AVArx vs NextMeds

AVArx
Graded #427

Lower grade

vs+10.199999999999996
NextMeds
Graded #207

Higher grade

The verdict

NextMeds takes it — 66.1/100 to 55.9/100.

NextMeds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NextMeds is a cash-pay telehealth platform offering compounded semaglutide and compounded tirzepatide on a flat monthly membership — one price bundling the medication (if prescribed), telehealth visits, a…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNextMeds +10
45
55
Dose & formulationNextMeds +24
40
64
Clinical oversightEven
77
77
Labs & monitoringNextMeds +9
52
61
FulfillmentAVArx +1
85
84
Contract termsNextMeds +20
41
61
AVArx · left barNextMeds · right bar

The numbers

MetricAVArxNextMeds
WeighScore55.9/10066.1/100
GradeCC
Scorecard rank#427#207
SemaglutideNot disclosed$129/mo (plus a separate fee, compounded)
TirzepatideNot disclosed$179/mo (plus a separate fee, compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
AVArx

Graded #427 · C

Strengths

  • Publishes exactly which states require a live audio or video visit before a prescription, which almost no competitor discloses
  • Names its prescribing group, Arora Health & Aesthetics, and gives a medical compliance contact
  • Terms state service is available to residents of all 50 states, and the shipping policy matches
  • Dates its own editorial reviews on treatment pages
  • HSA/FSA accepted with receipts provided for reimbursement

Where it loses points

  • No price is published anywhere on the site, on treatment pages or in the intake, so you cannot compare before starting a visit
  • Never states whether its semaglutide and tirzepatide are compounded or brand-name
  • No dispensing pharmacy is named, only licensed pharmacies in our network
  • Cancellation terms are not published, only presented at checkout
  • Prescriptions cannot be returned once dispensed, and the refund policy is otherwise unstated
NextMeds

Graded #207 · C

Strengths

  • Flat monthly membership bundles the medication, telehealth visits, a 1:1 care coach and a licensed registered dietitian — one price, no hidden fees
  • Same price every dose, no auto-renewal, cancel anytime; free shipping and no insurance needed (FSA eligible)
  • Names a compounding pharmacy partner (Foothills Pharmacy) and states it services all 50 states
  • Free, no-obligation online assessment before you pay anything

Where it loses points

  • Shows a LegitScript 'approval' but links only a generic directory search, not a verifiable seal — we couldn't independently confirm it
  • Promo-driven pricing with a countdown timer and 'price increases' urgency; the standing membership is $129 (sema) / $179 (tirz)
  • A technology platform that coordinates care, not the medical provider; individual clinicians and a medical director aren't named on the site
  • Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard